SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.42% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.94%.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 3.94%, a 5.97% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-09-30 was 4.19%.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.32%.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 3.97%, a 8.10% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.32%, a 7.49% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.67%, a 31.18% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.56%, a 157.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.42% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 3.94% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 3.97% 10-K · filed 2026-03-09 | |||
| 2025-09-30 | 3.94% 10-Q · filed 2025-11-14 | 3.97% 10-Q · filed 2025-11-14 | ||
| 2024-12-31 | 4.32% 10-K · filed 2026-03-09 | |||
| 2024-09-30 | 4.19% 10-Q · filed 2025-11-14 | 4.32% 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | 4.32% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 4.32% 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 4.67% 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 3.90% 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-08 | 3.90% 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | 3.56% 10-K · filed 2024-03-29 | |||
| 2022-09-30 | 3.56% 10-Q · filed 2023-11-13 | 3.56% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 3.03% 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | 2.41% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 1.38% 10-K · filed 2023-04-14 | |||
| 2021-09-30 | 0.59% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 0.59% 10-Q · filed 2022-08-10 | 0.59% 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |